japanes
enceph
je
signific
human
health
concern
asia
indonesia
part
australia
billion
peopl
potenti
risk
infect
japanes
enceph
viru
jev
caus
agent
je
given
risk
human
health
theoret
potenti
jev
use
bioweapon
develop
safe
effect
vaccin
prevent
jev
infect
vital
preserv
human
health
develop
vaccin
je
began
formalininactiv
mous
brainderiv
vaccin
vaccin
shown
induc
protect
immun
respons
effect
mous
brainderiv
vaccin
still
use
may
last
lot
biken
jevax
expir
develop
modern
je
vaccin
util
cell
culturederiv
virus
improv
manufactur
process
well
remov
potenti
allergen
toxin
significantli
improv
vaccin
safeti
china
develop
liveattenu
vaccin
proven
induc
protect
immun
follow
singl
inocul
addit
chimer
vaccin
viru
incorpor
prm
e
structur
protein
deriv
liveattenu
je
vaccin
liveattenu
yellow
fever
vaccin
viru
backbon
current
clinic
trial
articl
provid
summari
je
vaccin
develop
ongo
clinic
trial
also
discuss
potenti
risk
jev
bioweapon
focu
viru
sustain
use
weapon
japanes
enceph
viru
jev
mosquitoborn
flaviviru
famili
flavivirida
genu
flaviviru
endem
eastern
southern
asia
indonesia
isol
northern
part
australia
diseas
similar
japanes
enceph
je
first
describ
late
first
clearli
identifi
epidem
occur
japan
second
larg
epidem
follow
regular
outbreak
japan
last
signific
outbreak
je
japan
occur
je
first
report
korea
china
nepal
number
asian
countri
sinc
je
first
identifi
india
subsequ
becom
signific
health
concern
india
estim
case
per
year
morbid
rate
case
per
popul
jev
identifi
human
case
torr
strait
region
australia
subsequ
incurs
cape
york
area
mainland
australia
je
exist
two
distinct
epidemiolog
zone
je
consid
endem
tropic
region
asia
indonesia
case
occur
year
round
larg
outbreak
occur
raini
season
mosquito
popul
increas
temper
region
asia
je
occur
epidem
outbreak
warm
summer
month
mosquito
abund
jev
member
je
serocomplex
flavivirus
also
includ
west
nile
viru
murray
valley
enceph
viru
st
loui
enceph
viru
among
other
first
isol
jev
type
strain
nakayama
made
tokyo
brain
fatal
human
case
subsequ
isol
viru
china
occur
isol
strain
mosquito
fatal
human
case
respect
earli
immunolog
character
nakayama
strain
separ
virus
two
differ
immunotyp
subsequ
monoclon
antibodi
analysi
identifi
least
five
differ
antigen
subtyp
jev
circul
sinc
isol
nakayama
strain
subsequ
genet
analysi
determin
je
subgroup
consist
genotyp
virus
th
genotyp
consist
singl
isol
muar
strain
isol
brain
fatal
human
case
muar
malaysia
four
five
jev
genotyp
genotyp
isol
indonesia
genotyp
histor
widespread
genotyp
shift
toward
predomin
genotyp
seem
occur
jev
isol
transmit
number
mosquito
speci
includ
multipl
culex
aed
speci
virus
within
je
serocomplex
howev
typic
transmit
cx
spp
mosquito
mosquitoborn
flavivirus
ie
dengu
yellow
fever
virus
typic
transmit
ae
spp
mosquito
principl
vector
jev
asia
cx
tritaeniorrhynchu
although
member
cx
vishnui
group
also
associ
transmiss
jev
jev
maintain
mosquito
popul
transovari
transstadi
transmiss
viru
surviv
winter
dormant
mosquito
princip
natur
reservoir
jev
includ
bird
pig
mani
bird
speci
infect
jev
develop
diseas
indic
bird
may
signific
contributor
viral
mainten
natur
larg
water
bird
particularli
heron
egret
suggest
play
role
viral
distribut
move
viru
long
distanc
along
migratori
flyway
expans
cattl
egret
rang
particular
suggest
coincid
spread
jev
domest
swine
consid
amplifi
host
jev
develop
high
viral
titer
without
manifest
diseas
pig
infect
mosquito
feed
pig
becom
infect
transmit
viru
pig
bird
human
vertebr
mani
region
jev
endem
area
pig
live
rel
close
proxim
human
allow
effici
transmiss
viru
pig
popul
human
popul
pig
gener
show
sign
clinic
diseas
although
studi
japan
indic
jev
caus
abort
pregnant
sow
due
role
pig
transmiss
jev
cull
pig
popul
frequent
respons
jev
outbreak
cattl
hors
gener
consid
dead
end
host
jev
infect
develop
suffici
viremia
effect
transmiss
viru
bite
mosquito
cattl
seroconvert
follow
infect
also
suggest
jev
may
associ
abort
pregnant
cow
infect
hors
sever
shown
develop
neurolog
diseas
studi
found
rate
clinic
diseas
per
hors
case
fatal
rate
incid
rate
decreas
per
widespread
vaccin
hors
approxim
billion
peopl
thought
risk
jev
infect
region
case
death
report
annual
estim
case
per
year
suggest
signific
proport
suscept
individu
children
je
gener
consid
childhood
diseas
endem
region
countri
jev
endem
ie
warmer
latitud
case
occur
throughout
year
although
increas
case
gener
note
increas
mosquito
abund
wet
season
cooler
latitud
jev
gener
occur
epidem
outbreak
warmer
month
mosquito
preval
jev
infect
asymptomat
develop
febril
syndrom
headach
progress
mening
andor
enceph
sever
enceph
case
initi
present
nondescript
febril
ill
sever
headach
accompani
dizzi
nausea
vomit
diarrhea
addit
sign
neurolog
diseas
may
includ
photophobia
alter
conscious
masklik
faci
muscular
rigid
evid
tremor
seizur
particularli
children
death
usual
occur
day
follow
onset
symptom
approxim
case
fatal
rate
around
mani
survivor
je
cognit
andor
physic
sequela
includ
upper
lower
motor
neuron
impair
deform
arm
leg
feet
languag
impair
seizur
also
evid
chronic
persist
infect
uncommon
jev
singlestrand
positivesens
rna
viru
singl
open
read
frame
encod
singl
polyprotein
polyprotein
subsequ
cleav
three
structur
capsid
c
membran
envelop
e
seven
nonstructur
protein
flank
viral
protein
code
region
untransl
region
structur
protein
e
princip
protein
viral
particl
wherein
e
protein
primari
viral
antigen
also
serv
receptor
bind
fusion
protein
structur
flaviviru
e
protein
first
solv
tickborn
enceph
viru
subsequ
dengu
viru
addit
cryoelectron
microscopi
analys
intact
preand
postfusogen
flaviviru
particl
serv
clearli
defin
flaviviru
attach
fusion
process
viral
protein
immatur
version
prm
serv
protect
e
protein
viru
assembl
prevent
inadvert
fusion
host
membran
exocytosi
proper
assembl
releas
flaviviru
particl
requir
coexpress
prm
e
gene
individu
viru
import
understand
develop
novel
vaccin
strategi
flavivirus
number
therapeut
strategi
test
treatment
je
includ
compound
test
rodent
human
limit
efficaci
two
drug
licens
unit
state
pentoxifyllin
mycophenol
acid
mpa
shown
protect
effect
test
jev
challeng
juvenil
mice
mpa
immunosuppress
typic
use
transplant
patient
use
human
practic
could
potenti
increas
suscept
diseas
secondari
infect
pentoxifyllin
licens
use
reduc
blood
viscos
case
vascular
occlus
poor
circul
extrem
typic
offlabel
use
includ
treatment
impot
ulcer
stroke
clinic
studi
shown
reduct
inflammatori
respons
treatment
patient
chronic
hepat
c
yet
pentoxifyllin
shown
ineffect
treatment
sar
coronaviru
infect
mice
mpa
effect
human
physiolog
question
efficaci
anim
model
rais
signific
doubt
util
pentoxifyllin
treatment
je
minocyclin
semisynthet
deriv
tetracyclin
also
shown
protect
mice
follow
challeng
jev
initi
treatment
hour
post
infect
initi
shown
earli
minocyclin
effect
retroviru
infect
recent
reduc
west
nile
viru
propag
cell
cultur
specif
mechan
action
treat
jev
unclear
increas
evid
minocyclin
reduc
bloodbrain
barrier
damag
limit
product
reactiv
oxygen
speci
induct
apoptosi
also
associ
induc
neuron
repair
report
effect
minocyclin
known
toler
human
suggest
agent
test
clinic
trial
treatment
je
arctigenin
lignin
deriv
greater
burdock
arctium
lappa
also
shown
effect
postchalleng
treatment
jev
infect
juvenil
mous
model
interestingli
arctigenin
also
shown
decreas
activ
henc
apoptosi
reduc
reactiv
oxygen
speci
block
jevinduc
downregul
superoxid
dismutas
product
ino
upregul
subsequ
studi
shown
arctigenin
protect
mice
challeng
influenza
similar
activ
minocyclin
arctigenin
interest
clearli
point
import
control
apoptosi
reactiv
oxygen
speci
jev
infect
brain
clinic
studi
use
interferon
two
patient
initi
look
promis
subsequ
random
doubleblind
placebo
control
trial
found
interferon
effect
treatment
je
similarli
control
trial
use
ribavirin
oral
administr
treatment
je
found
ribavirin
effect
reduc
mortal
associ
je
current
avail
licens
therapeut
option
treatment
je
support
care
remain
primari
treatment
option
identif
potenti
therapeut
option
particularli
minocyclin
encourag
increas
optim
identif
appropri
treatment
option
one
biggest
challeng
drug
mention
effect
clinic
set
symptomat
patient
arriv
hospit
case
known
exposur
eg
laboratori
set
intent
accident
releas
earli
prevent
viral
replic
andor
neurolog
damag
may
effect
howev
patient
begin
show
neurolog
sign
diseas
common
je
case
therapeut
option
may
even
limit
jev
consid
potenti
biothreat
agent
due
potenti
threat
human
health
also
agricultur
concern
jev
affect
pig
cattl
hors
popul
evid
former
soviet
union
japan
evalu
use
jev
bioweapon
howev
clear
whether
viru
ever
success
weapon
would
success
bioweapon
direct
aerosol
challeng
laboratori
control
condit
shown
produc
lethal
infect
squirrel
monkey
hamster
mice
howev
clear
jev
could
success
deliv
aerosol
stabliti
environ
would
make
effect
weapon
also
evid
jev
natur
transmit
humantohuman
contact
would
significantli
hinder
util
weapon
human
popul
effect
use
jev
weapon
immedi
bring
mind
idea
initi
widespread
outbreak
acut
diseas
signific
morbid
case
jev
establish
outbreak
progress
beyond
initi
point
infect
would
requir
appropri
ecolog
factor
present
potenti
jev
mainten
environ
requir
consider
presenc
compet
mosquito
vector
potenti
amplifi
host
princip
mosquito
vector
asia
cx
tritaeniorhynchu
found
north
america
relat
speci
cx
pipien
cx
quinquefasciatu
cx
tarsali
found
north
america
consid
compet
vector
jev
aed
spp
mosquito
includ
ae
aegypti
ae
albopictu
present
north
america
also
shown
transmit
jev
much
less
effici
cx
speci
exampl
introduct
west
nile
viru
wnv
unit
state
demonstr
st
loui
enceph
viru
slev
endem
part
north
america
addit
virus
je
serocomplex
could
introduc
dissemin
sustain
ecosystem
requir
amplifi
host
mainten
jev
north
america
may
potenti
limit
spread
asia
jev
typic
rural
diseas
frequent
found
concert
water
bird
pig
environ
peopl
live
close
proxim
speci
asia
domest
pig
signific
compon
jev
transmiss
cycl
well
known
amplifi
host
jev
develop
significantli
high
viremia
effect
transmiss
mosquito
north
america
domest
livestock
typic
held
larg
number
close
proxim
human
popul
center
reduc
likelihood
explos
outbreak
human
popul
howev
possibl
jev
introduc
maintain
larg
piggeri
consid
real
threat
farm
industri
even
though
potenti
impact
human
health
limit
potenti
local
je
outbreak
near
small
farm
piggeri
remain
risk
viru
introduc
compet
vector
present
suffici
number
facilit
effici
transmiss
viru
larg
water
bird
heron
egret
play
import
role
transmiss
cycl
jev
develop
suffici
high
viremia
allow
infect
bite
mosquito
wide
migratori
rang
allow
dissemin
viru
multipl
speci
heron
egret
found
throughout
north
america
could
provid
mean
viru
dissemin
jev
introduc
introduct
jev
north
america
either
natur
intent
mean
could
signific
immedi
health
agricultur
impact
abil
viru
maintain
question
howev
also
note
abil
wnv
effect
maintain
north
america
question
viru
endem
rel
isol
larg
piggeri
rural
area
reduc
effici
mainten
transmiss
viru
howev
introduct
jev
north
america
nonendem
region
could
signific
econom
impact
pork
industri
cull
often
initi
respons
je
outbreak
presenc
jev
porcin
popul
could
neg
impact
export
swine
pork
product
discoveri
caus
agent
je
came
first
effort
develop
vaccin
prevent
infect
limit
expans
outbreak
initi
effort
util
mice
vaccin
develop
technolog
known
effect
develop
cell
cultur
techniqu
vaccin
product
move
control
predict
vaccin
platform
recent
year
vaccin
develop
begun
util
recombin
technolog
develop
protein
subunit
vaccin
chimer
viru
vaccin
latter
effort
util
nonstructur
protein
backbon
yellow
fever
viru
yfv
vaccin
jev
prm
e
structur
protein
integr
genom
novel
vaccin
shown
promis
current
clinic
trial
tabl
incid
advers
reaction
follow
vaccin
decreas
develop
improv
manufactur
techniqu
techniqu
includ
limit
use
primari
anim
growth
substrat
reduct
preserv
use
eg
thimerisol
improv
adjuv
improv
vaccin
puriti
good
manufactur
practic
gmp
addit
order
improv
data
interpret
clinic
trial
recommend
made
world
health
organ
defin
correl
immun
jev
vaccin
plaqu
reduct
neutral
test
prnt
valu
valu
gener
accept
demonstr
protect
respons
flaviviru
vaccin
addit
demonstr
vaccin
efficaci
made
use
licens
jev
vaccin
direct
compar
determin
noninferior
develop
first
gener
je
vaccin
began
shortli
discoveri
jev
caus
agent
je
collabor
effort
rockefel
institut
us
armi
result
develop
inactiv
mous
brainderiv
vaccin
develop
chick
embryo
base
vaccin
japan
first
vaccin
formalininactiv
infect
mous
brain
homogen
base
nakayama
strain
jev
use
sinc
howev
nation
standard
develop
je
vaccin
modifi
cours
time
reduc
remov
brain
materi
vaccin
avoid
potenti
neurolog
complic
improv
puriti
vaccin
ultracentrifug
protein
precipit
addit
strain
use
vaccin
product
japan
chang
type
strain
nakayama
latter
viru
higher
yield
vaccin
product
thought
efficaci
wider
rang
jev
strain
howev
studi
directli
compar
vaccin
deriv
nakayama
beij
strain
identifi
signific
differ
efficaci
two
vaccin
nakayama
strain
still
use
vaccin
develop
sever
asian
countri
includ
korea
vietnam
india
use
japan
thailand
inactiv
mousebrain
vaccin
market
either
research
foundat
microbi
diseas
osaka
univers
distribut
sanofipasteur
februari
product
distribut
vaccin
ceas
last
lot
vaccin
expir
may
develop
live
attenu
vaccin
see
appear
provid
strong
candid
effect
singl
dose
vaccin
vaccinerel
advers
event
howev
resist
circl
use
liveattenu
vaccin
due
concern
regard
viral
revers
virul
use
live
vaccin
potenti
immunocompromis
individu
furthermor
inactiv
mous
brainderiv
vaccin
could
potenti
contain
contamin
biolog
materi
could
caus
allerg
reaction
diseas
subsequ
develop
inactiv
cell
cultur
vaccin
jev
princip
focu
use
cell
cultur
system
provid
sever
advantag
use
infect
mous
brain
vaccin
product
first
cost
gener
viru
cell
cultur
much
cost
effect
use
mice
second
appropri
cell
cultur
system
vero
cell
devoid
neurolog
compon
caus
concern
inactiv
mous
brain
vaccin
third
qualiti
control
easier
cell
cultur
vaccin
compon
vaccin
care
regul
avoid
presenc
serum
antibiot
potenti
immunogen
fourth
virus
establish
immunogen
efficaci
use
develop
vaccin
china
initi
use
strain
jev
cell
cultur
base
vaccin
gener
phk
primari
hamster
kidney
cell
inactiv
cellcultur
base
vaccin
move
vero
nonhuman
primat
kidney
cell
cultur
system
vero
cellbas
vaccin
licens
princip
inactiv
je
vaccin
current
use
china
two
vero
cellbas
vaccin
current
use
japan
inactiv
vaccin
use
strain
current
use
vaccin
jebik
v
produc
biken
induc
higher
neutral
indic
mous
trial
inactiv
mous
brainderiv
vaccin
equival
dose
jebik
v
use
japan
sinc
jeimmugen
inj
produc
kaketsuken
vaccin
also
base
strain
jev
vaccin
licens
use
japan
current
undergo
addit
clinic
trial
children
korea
inactiv
cell
culturebas
vaccin
use
attenu
strain
licens
use
mani
countri
transit
inactiv
mous
brain
jevax
vaccin
final
dose
expir
may
new
vaccin
develop
intercel
known
australia
approv
use
adult
vaccin
person
year
age
unit
state
europ
canada
australia
hong
kong
switzerland
vaccin
current
undergo
number
clinic
trial
determin
safeti
efficaci
children
clinic
trial
adult
shown
similar
immunogen
toler
compar
jevax
vaccin
also
shown
compat
previou
vaccin
tickborn
enceph
viru
covaccin
hepat
viru
current
dose
recommend
unit
state
indic
two
dose
initi
seri
administ
day
apart
person
year
age
booster
schedul
determin
empir
publish
studi
indic
presenc
protect
antibodi
titer
month
initi
dose
regimen
unit
state
vaccin
licens
use
peopl
year
age
may
final
lot
jevax
reserv
use
minor
lot
expir
subsequ
current
licens
pediatr
vaccin
jev
vaccin
avail
unit
state
pediatr
clinic
trial
use
vaccin
recent
complet
india
addit
studi
ongo
philippin
unit
state
jev
vaccin
specif
avail
pediatr
use
asia
updat
ongo
clinic
trial
numer
therapeut
vaccin
found
wwwbiocanarycom
wwwclinicaltrialsgov
tabl
inactiv
mous
brain
vaccin
proven
safe
efficaci
cours
nearli
year
clinic
use
efficaci
mous
brainderiv
vaccin
shown
indirectli
decreas
number
je
case
area
signific
vaccin
coverag
addit
two
specif
clinic
trial
children
evalu
vaccin
protect
one
taiwan
thailand
shown
vaccin
protect
efficaci
follow
two
dose
vaccin
regimen
improv
content
puriti
mous
brainderiv
vaccin
cours
time
improv
safeti
vaccin
reduc
concern
regard
allerg
reaction
vaccin
advers
neurolog
event
report
side
effect
follow
vaccin
includ
local
tender
swell
approxim
vaccine
vaccin
children
japan
show
similar
reaction
sever
complic
headach
myalgia
fever
occur
vaccine
occurr
sever
neurolog
complic
includ
acut
dissemin
encephalomyel
adem
occur
rate
per
vaccin
given
japan
appar
higher
frequenc
denmark
lower
frequenc
unit
state
occurr
adem
exclus
je
vaccin
also
associ
number
vaccin
includ
rabi
measl
mump
smallpox
influenza
hepat
b
typic
associ
primari
vaccin
adem
also
occur
postinfecti
complic
follow
mani
type
viral
bacteri
infect
inactiv
cell
culturederiv
vaccin
also
shown
safe
efficaci
human
phk
cellderiv
vaccin
use
china
shown
protect
efficaci
trial
china
million
dose
phk
vaccin
distribut
annual
china
prior
licensur
liveattenu
vaccin
vero
cellbas
vaccin
also
shown
safe
number
clinic
trial
advers
event
seen
studi
similar
seen
follow
vaccin
mous
brainderiv
vaccin
includ
pain
tender
vaccin
site
although
direct
protect
studi
report
vaccin
vaccin
shown
produc
strong
protect
ie
neutral
antibodi
respons
sever
studi
use
twodos
primari
vaccin
regimen
shown
improv
protect
antibodi
respons
vaccine
demonstr
protect
antibodi
respons
day
post
immun
neutral
antibodi
titer
remain
protect
level
vaccine
month
postvaccin
mention
ongo
clinic
trial
provid
substanti
data
regard
qualiti
vaccin
next
sever
year
chines
scientist
began
develop
liveattenu
je
vaccin
base
strain
vaccin
current
produc
phk
cell
chegdu
institut
biolog
product
licens
china
million
dose
produc
sinc
licensur
vaccin
also
licens
nepal
korea
sri
lanka
addit
licensur
current
sought
vaccin
compon
childhood
immun
program
nepal
china
unlik
inactiv
viru
vaccin
vaccin
requir
singl
dose
induc
protect
respons
vaccin
vaccin
choic
china
inactiv
phk
cellbas
vaccin
sinc
develop
million
dose
live
attenu
vaccin
produc
china
million
dose
administ
children
vaccin
proven
quit
effect
efficaci
follow
singl
inocul
efficaci
evalu
year
follow
singl
dose
addit
studi
indic
efficaci
follow
boost
year
initi
inocul
recommend
dose
strategi
vaccin
two
dose
schedul
one
week
apart
recommend
boost
month
follow
initi
vaccin
sever
safeti
studi
perform
china
shown
signific
indic
advers
event
follow
vaccin
indic
viral
revers
neurovirul
phenotyp
scientist
oravax
describ
product
chimerivaxj
novel
vaccin
incorpor
structur
protein
prm
e
liveattenu
jev
vaccin
strain
nonstructur
protein
backbon
liveattenu
yfv
vaccin
strain
chimerivaxj
shown
immunogen
protect
small
scale
nonhuman
primat
studi
follow
stringent
intracerebr
ic
challeng
reduc
neurovirul
follow
ic
challeng
suckl
mice
subsequ
analys
provid
efficaci
data
primat
also
led
develop
addit
vaccin
platform
relat
flavivirus
dengu
viru
west
nile
viru
initi
clinic
trial
chimerivaxj
vaccin
shown
induc
shortterm
viremia
well
toler
induc
product
protect
antibodi
subsequ
analys
found
chimerivaxj
protect
four
princip
jev
genotyp
mous
model
addit
mosquito
fed
artifici
blood
meal
contain
high
titer
chimerivaxj
becom
infect
viru
indic
mosquito
unlik
transmit
viru
vaccin
individu
anoth
host
chimerivaxj
known
jecv
manufactur
acambi
sanofiaventi
proven
safe
immunogen
effect
number
human
trial
trial
involv
adult
volunt
sever
ongo
phase
ii
phase
iii
clinic
trial
involv
adult
children
month
age
wwwclinicaltrialsgov
je
signific
health
concern
local
popul
travel
part
asia
indonesia
effect
bioweapon
limit
inabl
jev
easili
transmit
humantohuman
aerosol
limit
util
jev
weapon
use
safe
effect
vaccin
probabl
inabl
easili
maintain
natur
would
limit
impact
viru
nonn
habitat
jev
vaccin
current
use
develop
shown
safe
effect
clinic
trial
although
use
novel
vaccin
children
limit
countri
due
lack
clinic
safeti
data
proven
efficaci
inactiv
vaccin
popul
support
emerg
use
outbreak
